- Home
- HOOD vs BIIB Comparison
HOOD vs BIIB Comparison
Compare HOOD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOD
- BIIB
- Stock Information
- Founded
- HOOD 2013
- BIIB 1978
- Country
- HOOD United States
- BIIB United States
- Employees
- HOOD N/A
- BIIB N/A
- Industry
- HOOD Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- HOOD Technology
- BIIB Health Care
- Exchange
- HOOD Nasdaq
- BIIB Nasdaq
- Market Cap
- HOOD 29.0B
- BIIB 25.1B
- IPO Year
- HOOD 2021
- BIIB 1991
- Fundamental
- Price
- HOOD $32.32
- BIIB $159.99
- Analyst Decision
- HOOD Buy
- BIIB Buy
- Analyst Count
- HOOD 16
- BIIB 25
- Target Price
- HOOD $26.60
- BIIB $260.48
- AVG Volume (30 Days)
- HOOD 20.8M
- BIIB 1.7M
- Earning Date
- HOOD 10-30-2024
- BIIB 10-30-2024
- Dividend Yield
- HOOD N/A
- BIIB N/A
- EPS Growth
- HOOD N/A
- BIIB 10.05
- EPS
- HOOD 0.59
- BIIB 11.06
- Revenue
- HOOD $2,408,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- HOOD $41.18
- BIIB N/A
- Revenue Next Year
- HOOD $6.38
- BIIB N/A
- P/E Ratio
- HOOD $54.65
- BIIB $14.46
- Revenue Growth
- HOOD 35.74
- BIIB N/A
- 52 Week Low
- HOOD $7.93
- BIIB $159.60
- 52 Week High
- HOOD $34.32
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- HOOD 67.77
- BIIB 20.34
- Support Level
- HOOD $31.46
- BIIB $170.71
- Resistance Level
- HOOD $34.10
- BIIB $175.86
- Average True Range (ATR)
- HOOD 1.67
- BIIB 5.21
- MACD
- HOOD 0.45
- BIIB -1.16
- Stochastic Oscillator
- HOOD 82.33
- BIIB 1.41
About HOOD Robinhood Markets Inc.
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.